Earnings Call · Q3 FY2025·2025-11-13

Q3 25EPS +17.02%·Rev n/aQ2 25EPS +16.67%·Rev n/aQ1 25EPS +2.33%·Rev n/aQ4 24EPS -5.88%·Rev n/a⚠ consensus missing

Lantern Pharma Inc. LTRN

Panna Sharma — Chief Executive Officer

David Margrave — Chief Financial Officer

−0.6%1d on move date+1.1% vs SPY3d−3.4%5d−6.0%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LTRN calls or request research access.

More LTRN calls Browse calls Request research access